Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus rating of “Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.0909.

Several equities analysts have weighed in on TSHA shares. Needham & Company LLC lifted their target price on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 19th.

Insider Transactions at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the sale, the chief executive officer owned 2,949,569 shares in the company, valued at $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently modified their holdings of the company. B Group Inc. lifted its holdings in Taysha Gene Therapies by 43.4% during the 2nd quarter. B Group Inc. now owns 1,800,556 shares of the company’s stock worth $4,159,000 after buying an additional 545,000 shares during the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $1,890,000. GSA Capital Partners LLP lifted its stake in Taysha Gene Therapies by 969.0% during the third quarter. GSA Capital Partners LLP now owns 477,749 shares of the company’s stock worth $1,562,000 after purchasing an additional 433,059 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in Taysha Gene Therapies in the third quarter valued at approximately $6,207,000. Finally, Affinity Asset Advisors LLC purchased a new position in Taysha Gene Therapies in the second quarter valued at approximately $462,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $4.07 on Friday. The company’s 50 day simple moving average is $4.58 and its 200-day simple moving average is $4.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $6.02. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.97 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 56.64%. The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. As a group, equities research analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.